stage iv uterine corpus cancer ajcc v7
Showing 1 - 7 of 7
Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in United
Recruiting
- Endometrial Undifferentiated Carcinoma
- +6 more
- Capivasertib
- +4 more
-
Birmingham, Alabama
- +741 more
Feb 2, 2023
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma Trial in Canada, United States
Active, not recruiting
- Advanced Endometrial Carcinoma
- +4 more
- Cabozantinib S-malate
- Nivolumab
-
Phoenix, Arizona
- +33 more
Nov 1, 2022
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma Trial in
Active, not recruiting
- Endometrial Adenosquamous Carcinoma
- +9 more
- Cabozantinib S-malate
- +2 more
-
Duarte, California
- +18 more
Oct 15, 2022
Collecting Blood Samples From and Without Cancer to Evaluate
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +61 more
- Questionnaire Administration
- Biospecimen Collection
- (no location specified)
Apr 12, 2022
Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7, Stage I Fallopian Tube Cancer AJCC v6 and v7 Trial in New
Withdrawn
- Endometrial Carcinoma
- +55 more
- Internet-Based Intervention
- +3 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Apr 16, 2021
Endometrial Adenocarcinoma, ERBB2 Gene Amplification, Recurrent Uterine Corpus Carcinoma Trial in Philadelphia (Laboratory
Completed
- Endometrial Adenocarcinoma
- +4 more
- Laboratory Biomarker Analysis
- Trastuzumab
-
Philadelphia, PennsylvaniaGynecologic Oncology Group
Jul 30, 2019
Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7 Trial
Unknown status
- Recurrent Uterine Corpus Carcinoma
- +2 more
- (no location specified)
Mar 8, 2019